Search Results - "Megna, Matteo"

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis.

Authors: Dapavo, Paolo Megna, Matteo Talamonti, Marina

Source: Dermatology Reports. 2025, Vol. 17 Issue 1, p1-5. 5p.

Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.

Authors: Megna, Matteo Ruggiero, Angelo Torta, Ginevra et al.

Source: Clinical & Experimental Dermatology. Oct2024, Vol. 49 Issue 10, p1186-1189. 4p.

Viral reactivation following COVID-19 vaccination: a review of the current literature.

Authors: Martora, Fabrizio Megna, Matteo Battista, Teresa et al.

Source: Clinical & Experimental Dermatology. Jun2024, Vol. 49 Issue 6, p556-565. 10p.

Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study.

Authors: Megna, Matteo Ruggiero, Angelo Martora, Fabrizio et al.

Source: Journal of Clinical Medicine. May2024, Vol. 13 Issue 9, p2691. 9p.

Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study.

Authors: Megna, Matteo Balato, Anna Caccavale, Stefano et al.

Source: Journal of Clinical Medicine. May2024, Vol. 13 Issue 9, p2552. 9p.

TNF-alpha inhibitors reduce the incidence of PsA in patients with psoriasis: a propensity score-matched cohort study.

Authors: Piaserico, Stefano Megna, Matteo Bardazzi, Federico et al.

Source: Rheumatology. Nov2025, Vol. 64 Issue 11, p5803-5810. 8p.

The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study.

Authors: Cacciapuoti, Sara Megna, Matteo Salza, Emanuela et al.

Source: Journal of Dermatological Treatment. Dec2024, Vol. 35 Issue 1, p1-3. 3p.

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study.

Authors: Megna, Matteo Ruggiero, Angelo Battista, Teresa et al.

Source: Journal of Clinical Medicine. May2023, Vol. 12 Issue 9, p3233. 10p.

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study).

Authors: Chiricozzi, Andrea Megna, Matteo Giunta, Alessandro et al.

Source: Journal of Dermatological Treatment. 2023, Vol. 34 Issue 1, p1-6. 6p.

The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience – IL PSO (Italian Landscape Psoriasis).

Authors: Megna, Matteo¹ (AUTHOR)

Source: Clinical & Experimental Dermatology. Apr2025, Vol. 50 Issue 4, p858-859. 2p.

Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.

Authors: Megna, Matteo Tommasino, Nello Potestio, Luca et al.

Source: Journal of Dermatological Treatment. Sep2022, Vol. 33 Issue 6, p2813-2820. 8p.

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting.

Authors: Megna, Matteo Potestio, Luca Camela, Elisa et al.

Source: Dermatologic Therapy. Sep2022, Vol. 35 Issue 9, p1-8. 8p.

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection.

Authors: Megna, Matteo Patruno, Cataldo Bongiorno, Maria Rita et al.

Source: Journal of Dermatological Treatment. Aug2022, Vol. 33 Issue 5, p2629-2633. 5p.

Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study.

Authors: Megna, Matteo Potestio, Luca Ruggiero, Angelo et al.

Source: Journal of Dermatological Treatment. Aug2022, Vol. 33 Issue 5, p2560-2564. 5p.

Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study.

Authors: Megna, Matteo Potestio, Luca Ruggiero, Angelo et al.

Source: Dermatologic Therapy. Jul2022, Vol. 35 Issue 7, p1-7. 7p.

Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role?

Authors: Megna, Matteo Caiazzo, Giuseppina Parisi, Melania et al.

Source: Clinical & Experimental Dermatology. May2022, Vol. 47 Issue 5, p918-925. 8p. 1 Color Photograph, 1 Diagram, 1 Chart, 1 Graph.

Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient.

Authors: Megna, Matteo Abategiovanni, Luisa Annunziata, Alberto et al.

Source: Dermatologic Therapy. May2022, Vol. 35 Issue 5, p1-4. 4p.

Eine kritische Neubewertung der Off-Label-Anwendung der photodynamischen Therapie zur Behandlung von nicht neoplastischen Hauterkrankungen.

Authors: Monfrecola, Giuseppe Megna, Matteo Rovati, Chiara et al.

Source: Kompass Dermatologie. 2022, Vol. 10 Issue 2, p54-63. 10p.

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience.

Authors: Megna, Matteo Fabbrocini, Gabriella Cinelli, Eleonora et al.

Source: Journal of Dermatological Treatment. Mar2022, Vol. 33 Issue 2, p1074-1078. 5p.

A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab.

Authors: Megna, Matteo Battista, Teresa Potestio, Luca et al.

Source: Journal of Cosmetic Dermatology. Mar2023, Vol. 22 Issue 3, p1146-1148. 3p.